NCT00835120: Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance |
|
|
| Completed | 4 | 34 | US | Pioglitazone, Actos | University Hospitals Cleveland Medical Center, National Alliance for Research on Schizophrenia and Depression, Takeda Pharmaceuticals North America, Inc. | Metabolic Syndrome, Bipolar Depression, Insulin Resistance | 04/13 | 04/13 | | |
